Physician profile
Craig Rich
NPI 1497720874
$5,850.35
in general payments reported to CMS, 2019-2025
32 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $640 · 2021: $487 · 2022: $885 · 2023: $933 · 2024: $765 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,905.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,112.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $823.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $689.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $459.05 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $384.67 | 2019-2022 | |
| Abbvie INC. | $382.88 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $309.05 | 2023-2025 | |
| Amgen INC. | $247.66 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.49 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $192.36 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Ardelyx, INC. | $148.46 | 2025 | Ibsrela |
| Amarin Pharma, INC. | $132.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $92.24 | 2019-2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $83.54 | 2019-2023 | |
| Daiichi Sankyo INC. | $65.33 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $41.78 | 2024 | Resmetirom |
| Astellas Pharma US INC | $41.64 | 2019-2020 | |
| Allergan, INC. | $40.48 | 2020 | |
| Dexcom, INC. | $38.62 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $37.16 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $36.65 | 2019-2024 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $31.32 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Pulmonx Corporation | $30.06 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Endogastric Solutions, INC | $30.01 | 2024 | Esophyx |
| Biogen, INC. | $26.34 | 2025 | Leqembi |
| Boston Scientific Corporation | $25.76 | 2025 | Watchman Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $21.38 | 2019 | |
| Ibsa Pharma INC. | $19.54 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.46 | 2019 | |
| Sanofi Pasteur INC. | $17.62 | 2023 | |
| Dynavax Technologies Corporation | $17.53 | 2023 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.